Venom immunotherapy: clinical efficacy, safety and contraindications

References

• Bilo MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy 2009;39:1467-76
   PubMed Web of Science ®Google Scholar
• Bokanovic D, Aberer W, Griesbacher A, et al. Prevalence of hymenoptera venom allergy and poor adherence to immunotherapy in Austria. Allergy 2011;66:1395-6
   Google Scholar
• Antonicelli L, Bilò MB, Napoli G, et al. European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? Eur Ann Allergy Clin Immunol 2003;35:199-203
   Google Scholar
• Ruëff F, Przybilla B, Biló Mb, et al. Predictors of severe systemic anaphylactic reactions in patients with hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology interest group on insect venom hypersensitivity. J Allergy Clin Immunol 2009;124:1047-54
   PubMed Web of Science ®Google Scholar
• Stoevesandt J, Hain J, Kerstan A, et al. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012;130:698-704
   Google Scholar
• Oude Elberink JN, De Monchy JG, Van Der Heide S, et al. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002;110:174-82
   PubMed Web of Science ®Google Scholar
• Bonifazi F, Jutel M, Biló BM, et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005;60:1459-70
   PubMed Web of Science ®Google Scholar
• Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011;127:S1-55
   PubMed Web of Science ®Google Scholar
• Roumana A, Pitsios C, Vartholomaios S, et al. The safety of initiating Hymenoptera immunotherapy at 1 microg of venom extract. J Allergy Clin Immunol 2009;124:379-81
   PubMed Web of Science ®Google Scholar
• Goldberg A, Yogev A, Confino-Cohen R. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Int Arch Allergy Immunol 2011;156:90-8
   Google Scholar
• Golden BK. Insect allergy. In: Adkinson FN, Busse WW, Bochner BS, et al. editors. Middleton’s allergy: principles and practice. 7th edition. Mosby Elsevier, New York; 2009. p. 1005-15
   Google Scholar
• Patella V, Florio G, Giuliano A et al. Hymenoptera venom immunotherapy: Tolerance and efficacy of an ultrarush protocol versus a rush and a slow conventional protocol. J Allergy (Cairo) 2012;192192
   Google Scholar
• Sturm G, Kränke B, Rudolph C, et al. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol 2002;110:928-33
   PubMed Web of Science ®Google Scholar
• Simioni L, Vianello A, Bonadonna P, et al. Efficacy of venom immunotherapy given every 3 or 4 months: a prospective comparison with the conventional regimen. Ann Allergy Asthma Immunol 2013;110:51-4
   PubMed Web of Science ®Google Scholar
• Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:1027-32
   PubMed Web of Science ®Google Scholar
• Bonadonna P, Gonzalez-de-Olano D, Zanotti R, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract 2013;1:474-8
   Google Scholar
• Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-61
   PubMed Web of Science ®Google Scholar
• Goldberg A, Confino-Cohen R. Bee venom immunotherapy – How early is it effective. J Allergy Clin Immunol 2009;123:241
   Google Scholar
• Roesch A, Boerzsoenyi J, Babilas P, et al. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population. J Dtsch Dermatol Ges 2008;6:292-7
   Google Scholar
• Ruëff F, Przybilla B, Biló MB, et al. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. PLoS One 2013;8(5):e63233
   Google Scholar
• Ruëff F, Vos B, Oude Elberink J, et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clin Exp Allergy 2014;44:736-46
   Google Scholar
• Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606-12
   PubMed Web of Science ®Google Scholar
• Hoffman DR. Fatal Reactions to Hymenoptera Stings. Allergy Asthma Proc 2003;24:123-7
   Google Scholar
• Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol 2008;100:162-5
   PubMed Web of Science ®Google Scholar
• Peternelj A, Silar M, Erzen R, et al. Basophil sensitivity in patients not responding to venom immunotherapy. Int Arch Allergy Immunol 2008;146:248-54
   Google Scholar
• Eržen R, Košnik M, Silar M, et al. Basophil response and the induction of a tolerance in venom immunotherapy: a long-term sting challenge study. Allergy 2012;67:822-30
   Google Scholar
• Niedoszytko M, Bruinenberg M, de Monchy J, et al. Changes in gene expression caused by insect venom immunotherapy responsible for the long-term protection of insect venom-allergic patients. Ann Allergy Asthma Immunol. 2011;106:502-10
   Google Scholar
• Mosbech H, Mueller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 2000;55:1005-10
   PubMed Web of Science ®Google Scholar
• Greenberger PA, Meyers SN, Kramer BL. Effects of beta-adrenergic and calcium antagonists on the development of anaphylactoid reactions from radiographic contrast media during cardiac angiography. J Allergy Clin Immunol 1987;80:698-702
   PubMed Web of Science ®Google Scholar
• Tunon-de-Lara JM, Villanueva P, Marcos M, et al. ACE inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet 1992;340:908
   PubMed Web of Science ®Google Scholar
• Ober AI, MacLean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol 2003;112:1008-9
   Google Scholar
• Laurent J, Smiejan JM, Bloch-Morot E, et al. Safety of Hymenoptera venom rush immunotherapy. Allergy 1997;52:94-6
   PubMedGoogle Scholar
• Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993;23:226-30
   PubMed Web of Science ®Google Scholar
• Goldberg A, Yogev A, Confino-Cohen R. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Int Arch Allergy Immunol 2011;156:90-8
   Google Scholar
• Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol 2003;91:405-10
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Frati F, Dell’Albani I, et al. Safety of hymenoptera venom immunotherapy: a systematic review. Expert Opin Pharmacother 2011;12:2527-32
   PubMed Web of Science ®Google Scholar
• Lockey RF, Turkeltaub PC, Olive ES, et al. The Hymenoptera venom study III: safety of venom immunotherapy. J Allergy Clin Immunol 1990;86:775-80
   PubMed Web of Science ®Google Scholar
• Mueller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-35
   Google Scholar
• Rueff F, Przybilla B, Bilo MB, et al. Predictors of side effects during the build-up phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010;126:105-11
   PubMed Web of Science ®Google Scholar
• Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006;61(Suppl 82):1-20
   PubMed Web of Science ®Google Scholar
• Cox L, Larenas-Linnemann D, Lockey RF, et al. Speaking the same language: the world allergy organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010;125:569-74. 574.e1-574
   PubMed Web of Science ®Google Scholar
• Potier A, Lavigne C, Chappard D, et al. Cutaneous manifestations of Hymenoptera and Diptera anaphylaxis: relationship to basal serum tryptase. Clin Exp Allergy 2009;39:717-25
   Google Scholar
• Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123:680-6
   PubMed Web of Science ®Google Scholar
• Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001;108:1027-32
   PubMed Web of Science ®Google Scholar
• Oude Elberink JNG, de Monchy JGR, Kors JW, et al. Fatal anaphylaxis after a yellow jacket sting in two patients with mastocytosis. J Allergy Clin Immunol 1997;99:153-4
   Google Scholar
• Kosnik M, Silar M, Bajrovic N, et al. High sensitivity of basophils predicts side-effects in venom immunotherapy. Allergy 2005;60:1401-6
   Google Scholar
• Korosec P, Ziberna K, Silar M, et al. Factors associated with side effects during the build-up phase of honeybee venom immunotherapy. Allergy 2014;69:S24-5
   Google Scholar
• Adamic K, Zidarn M, Bajrovic N, et al. The local and systemic side-effects of venom and inhaled-allergen subcutaneous immunotherapy. Wien Klin Wochenschr 2009;121:357-60
   Google Scholar
• Gorska L, Chelminska M, Kuziemski K, et al. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Int Arch Allergy Immunol 2008;147:241-5
   PubMed Web of Science ®Google Scholar
• Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001;107:81-6
   PubMed Web of Science ®Google Scholar
• Rueff F, Wolf H, Schnitker J, et al. Specific immunotherapy in honey bee venom allergy: a comparative study using aqueous and aluminium adsorbed preparations. Allergy 2004;59:589-95
   PubMedGoogle Scholar
• Bilo B, Roncarolo D, Falagiani P, et al. A new potential candidate for ITS of bee venom allergic patients. Allergy 2009;64(Suppl 90):140
   Google Scholar
• Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007;62:963-4
   PubMed Web of Science ®Google Scholar
• Galera C, Soohun N, Zankar N, et al. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009;19:225-9
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004;113:1129-36
   PubMed Web of Science ®Google Scholar
• Müller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005;115:606-10
   PubMed Web of Science ®Google Scholar
• Hepner MJ, Ownby DR, Anderson JA, et al. Risk of systemic reactions in patients taking beta-blocker drugs receiving allergy immunotherapy injections. J Allergy Clin Immunol 1990;85:407-11
   Google Scholar
• Stoevesandt J, Hain J, Stolze I, et al. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase. Clin Exp Allergy 2014;44:747-55
   PubMed Web of Science ®Google Scholar
• Linneberg A, Jacobsen RK, Jespersen L, et al. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 2012;129:413-19
   PubMed Web of Science ®Google Scholar
• Pitsios C, Demoly P, Bilò MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy 2015;24
   Google Scholar
• Fiorillo A, Fonacier L, Diola C. Safety of allergenic immunotherapy in systemic lupus. erythematosus. J Allergy Clin Immunol 2006;S264
   Google Scholar
• Marshall GDJr. AIDS, HIV-positive patients, and allergies. Allergy Asthma Proc 1999;20:301-4
   PubMed Web of Science ®Google Scholar
• Schwartz HJ, Golden DBK, Lockey RF. Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 1990;85:709-12
   PubMed Web of Science ®Google Scholar